India · Delayed Price · Currency is INR Alivus Life Sciences Company Description
Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally.
It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, immunosuppressant, respiratory and ophthalmologic agents, urology, and anti-infectives.
The company also provides contract development and manufacturing services to a range of multinational corporations and specialty companies.
It exports its products. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024.
The company was founded in 2001 and is based in Mumbai, India. Alivus Life Sciences Limited is a subsidiary of Nirma Limited.
| Country | India |
| Founded | 2001 |
| Industry | Medicinal Chemicals and Botanical Products |
| Employees | 2,203 |
| CEO | Yasir Rawjee |
Contact Details
Address: OIA House Mumbai, Maharashtra 400099 India | |
| Phone | 91 22 6829 7979 |
| Website | alivus.com |
Stock Details
| Ticker Symbol | 543322 |
| Exchange | Bombay Stock Exchange |
| Fiscal Year | April - March |
| Reporting Currency | INR |
| SIC Code | 2833 |
Key Executives
| Name | Position |
|---|---|
| Yasir Rawjee | Chief Executive Officer |
| Tushar Mistry | Chief Financial Officer |